Inaugurated in 1996, this was the first production area to come into being after the official establishment of our company. It currently serves as the GM gel workshop and the chemical microsphere workshop. Additionally, it houses some of our biopharmaceutical research and development functions and features a dedicated animal facility.

Launched in 2012, this facility is the major manufacturing base for the production of somatropin raw materials and formulations. It can accommodate nearly 2,000 employees and has an annual production capacity of 75 million somatropin units and serves as the primary hub for our supply chain system.

This project is designed for the international market, with a total investment of  CNY 3 billion($ 447.8 million). It is poised to become an integrated innovation hub for the biotechnological development, chemical pharmaceutical research and development, and the commercialization of transformative medicines.

Scheduled for operation in 2024, upon reaching full capacity, the park is projected to exceed an annual output value of  CNY 30 billion (abbr. $4.5 billion) and provide employment opportunities for 2,000 individuals. It will play a pivotal role in solidifying GenSci leading position in the domestic market for somatropin products and reinforce its advanced technological standing on the global stage.

The major site for production of polyethylene glycol (PEG) and formulation. The industrial park is equipped with state-of-the-art facilities and comprehensive support systems, adhering to the highest standards of Good Manufacturing Practice (GMP). The site is equipped with a comprehensive suite of facilities, including a formulation production plant, a chemical pharmaceutical research and development center, and a modern product testing and inspection center. We have also demonstrated our commitment to safety and quality by successfully obtaining certifications for ISO 14001 and ISO 45001 environmental and safety management systems.